According to the current ESMO-guidelines, it is regularly used prior to PRRT in small intestinal NET (SI-NET) G2 as well as P-NET G1-G3, while SI-NET G1 receive PRRT prior to mTOR-inhibitors [2]. Here, MTOR is linked to small intestine neuroendocrine neoplasm.